News & Updates
Filter by Specialty:
BOREAS highlights dupilumab potential in COPD
In the phase III BOREAS trial, the monoclonal antibody dupilumab conferred multiple benefits for individuals with chronic obstructive pulmonary disease (COPD) and type 2 (T2) inflammation.
BOREAS highlights dupilumab potential in COPD
27 Nov 2023
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
In the treatment of older patients with metastatic castration-resistant prostate cancer (mCRPC) who are considered unsuitable candidates for standard cabazitaxel (CBZ) regimens, treatment with CBZ at 16 mg/m2 (biweekly CBZ16) plus prophylactic granulocyte colony–stimulating factor (G-CSF) at each cycle helps reduce the risk of higher grade neutropenia and/or neutropenic complications while yielding similar clinical outcomes, according to the results of the phase III CABASTY trial.
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
27 Nov 2023
Treatment choices influence rescue medication use in asthma
In patients with poor asthma control, switching from fluticasone propionate (FP) monotherapy to inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA) combination therapy may help improve symptom control and reduce the use of reliever or rescue medications, according to a study.
Treatment choices influence rescue medication use in asthma
25 Nov 2023
Outpatient initiation of venetoclax safe, feasible in acute myeloid leukaemia
Initiation of venetoclax for acute myeloid leukaemia (AML) in the outpatient setting with a pharmacist-led interdisciplinary protocol is both feasible and safe, reports a study.